Focused On-demand Library for Probable 28S rRNA (cytosine(4447)-C(5))-methyltransferase

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We employ our advanced, specialised process to create targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

P46087

UPID:

NOP2_HUMAN

Alternative names:

Nucleolar protein 1; Nucleolar protein 2 homolog; Proliferating-cell nucleolar antigen p120; Proliferation-associated nucleolar protein p120

Alternative UPACC:

P46087; A1A4Z3; B3KPD6; Q05BA7; Q0P5S5; Q3KQS4; Q58F30

Background:

The Probable 28S rRNA (cytosine(4447)-C(5))-methyltransferase, also known as Nucleolar protein 1 and several other names, plays a crucial role in ribosomal large subunit assembly. It functions as an S-adenosyl-L-methionine-dependent methyltransferase, specifically targeting the C(5) position of cytosine 4447 in 28S rRNA. This activity is pivotal for the regulation of the cell cycle and supports the nucleolar activity associated with cell proliferation.

Therapeutic significance:

Understanding the role of Probable 28S rRNA (cytosine(4447)-C(5))-methyltransferase could open doors to potential therapeutic strategies.